⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034: Addressing Treatment Gaps in Bipolar Depression, Early Diagnosis, Patient Adherence, and Clinical Trial Effectiveness - ResearchAndMarkets.com
businesswire.com
BMY
VNDA
XENE
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
prnewswire.com
VNDA
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
prnewswire.com
VNDA
ANAB
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
prnewswire.com
VNDA
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
prnewswire.com
VNDA
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
prnewswire.com
VNDA
Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
prnewswire.com
VNDA